Shanghai, China – June 2026 – Royal Pharm is proud to announce the highly successful conclusion of our participation in CPHI Shanghai 2026, one of the most prominent pharmaceutical exhibitions in the Asia-Pacific region. Held at the Shanghai New International Expo Centre, this year's event provided an exceptional platform for us to connect with global industry leaders, showcase our latest innovations, and explore new collaborative opportunities in the pharmaceutical market.

Throughout the exhibition, the Royal Pharm booth attracted a significant number of visitors and potential clients. Our comprehensive display of high-quality active pharmaceutical ingredients (APIs) received widespread acclaim, with attendees expressing strong interest in our latest pipeline and commercial products.

1.Leading the Peptide Revolution: Retatrutide & Orforglipron

A major highlight of our exhibition was the overwhelming response to our advanced peptide products. As the industry continues to focus on metabolic diseases, our offerings of Retatrutide and Orforglipron generated immense buzz.

Orforglipron, a next-generation oral non-peptide GLP-1 receptor agonist, is currently making waves across the industry for its potential to offer a more convenient and cost-effective alternative to existing injectable weight management and type 2 diabetes treatments. Meanwhile, our high-purity Retatrutide continues to attract significant attention as a highly potent candidate in the obesity therapeutic space. We were thrilled to engage in in-depth technical discussions with numerous potential clients regarding the synthesis, quality control, and commercial supply of these groundbreaking molecules.

2.Advancing HIV Therapeutics: Lenacapavir

In addition to our metabolic portfolio, Royal Pharm also showcased our commitment to infectious disease treatments with our premium Lenacapavir. As a first-in-class long-acting HIV-1 capsule inhibitor, Lenacapavir represents a paradigm shift in HIV treatment and prevention, offering patients the potential for biannual dosing. Many attendees expressed strong interest in our high-quality API supply for this transformative drug, reflecting the growing global demand for innovative HIV therapies.

Thank You to Our Visitors and Partners!!!

The enthusiastic response at CPHI Shanghai 2026 has been truly inspiring. We extend our deepest gratitude to everyone who visited our booth, engaged in meaningful discussions, and showed interest in our products. Your trust and enthusiasm drive us to continuously improve our manufacturing capabilities and expand our product portfolio.